City of Chicago v. Janssen Pharmaceuticals, Inc.

2017 IL App (1st) 150870
CourtAppellate Court of Illinois
DecidedApril 6, 2017
Docket1-15-0870
StatusUnpublished
Cited by1 cases

This text of 2017 IL App (1st) 150870 (City of Chicago v. Janssen Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Appellate Court of Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
City of Chicago v. Janssen Pharmaceuticals, Inc., 2017 IL App (1st) 150870 (Ill. Ct. App. 2017).

Opinion

2017 IL App (1st) 150870

FIFTH DIVISION March 31, 2017

No. 1-15-0870

) Appeal from the THE CITY OF CHICAGO, ) Circuit Court of ) Cook County Plaintiff-Appellee, ) ) v. ) No. 13 L 10572 ) JANSSEN PHARMACEUTICALS, INC., ) ) Honorable Defendant-Appellant. ) Sanjay Tailor, ) Judge Presiding.

JUSTICE REYES delivered the judgment of the court, with opinion. Presiding Justice Gordon concurred in the judgment and opinion. Justice Lampkin specially concurred in the judgment and opinion.

OPINION

¶1 Defendant Janssen Pharmaceuticals, Inc. (Janssen) appeals the circuit court of Cook

County’s order denying a motion to enforce a protective order previously entered between

Janssen and plaintiff, the City of Chicago (City). On appeal, Janssen maintains that the

documents it provided to the City pursuant to the protective order were not subject to disclosure

under the Freedom of Information Act (FOIA) (5 ILCS 140/1 et seq. (West 2014)). Specifically,

Janssen argues that the documents are exempt from inspection and copying under two separate

provisions of FOIA as (1) their disclosure is specifically prohibited by State law (5 ILCS

140/7(1)(a) (West 2014)) and (2) the documents are trade secrets or commercial or financial

information furnished under a claim that they are confidential and such disclosure would cause 1-15-0870

competitive harm to Janssen’s business (5 ILCS 104/7(1)(g) (West 2014)). At oral argument, the

defendant argued only that their disclosure is prohibited by section 7(1)(a) (5 ILCS 140/7(1)(a)

(West 2014)). For the reasons that follow, we affirm.

¶2 BACKGROUND

¶3 Prior to filing the lawsuit, the City served Janssen with a subpoena pursuant to section 1­

22-050 of the False Claims chapter of the Chicago Municipal Code (Ordinance) (Chicago

Municipal Code § 1-22-050 (added Dec. 15, 2004), as it was seeking documents that pertained to

the City’s civil investigation into false claims submitted as a result of certain of Janssen’s

practices in marketing opioids, i.e. a synthetic narcotic. Janssen, however, declined to produce

the documents requested by the City. As a result, on September 23, 2013, the City filed the

instant suit due to Janssen’s failure to respond to the subpoena.

¶4 While the matter was pending in the circuit court, Janssen and the City negotiated a

“Confidentiality Stipulation and Protective Order” (protective order), which was entered by the

circuit court on November 12, 2013. The protective order provided in pertinent part that the

information produced by Janssen, regardless of confidentiality designation, could only be used in

accordance with the provisions of section 1-22-050(i) of the Ordinance, or as otherwise required

by law or court order. The City acknowledged in the protective order that the information

produced by Janssen may contain trade secrets or other confidential information and that Janssen

“considers this information to be protected and exempt from disclosure under the Illinois

Freedom of Information Act.” The protective order further provided that the City would notify

Janssen if a request was made by a third party to disclose the produced information so as to allow

Janssen “the opportunity to take steps to prevent disclosure; provided, however, that nothing in

this Protective Order shall be read to conflict with the City of Chicago’s duty to comply” with

1-15-0870

the public disclosure laws, including FOIA.

¶5 On November 20, 2013, the City withdrew its petition to enforce the subpoena without

prejudice and was granted leave to reinstate “before this Court in the event that further disputes

or issues arise between the parties with respect to the subpoena.” Janssen then produced 114,230

pages of documents to the City, many of which were marked “confidential” pursuant to the

protective order.

¶6 On June 2, 2014, the City filed suit against Janssen, Janssen’s parent, and various other

pharmaceutical companies alleging violations of the Ordinance. As a result of filing this lawsuit,

USA Today issued a FOIA request to the City seeking copies of documents in support of certain

claims the City asserted against Janssen. Pursuant to the protective order, the City notified

Janssen of the request and informed Janssen that it believed three documents were responsive to

USA Today’s request.

¶7 Ultimately, on October 22, 2014, Janssen filed a motion to enforce the protective order in

the circuit court alleging that the City was required to deny third-party requests brought under

FOIA pursuant to the protective order. Janssen further argued that the documents sought were

exempt from disclosure under section 7 of FOIA (5 ILCS 140/7 (West 2014)). Pertinent to this

appeal, Janssen specifically asserted two reasons the documents were exempt. First, that section

7(1)(a) prevented disclosure of the documents where the information sought was specifically

prohibited from disclosure by State law (5 ILCS 140/7(1)(a) (West 2014)). According to Janssen,

subsections (i) and (k) of the Ordinance (Chicago Municipal Code § 1-22-050(i), (k) (added Dec.

15, 2004)) qualified as such a “State law” as it manifested the required legislative intent to

prohibit public disclosure of subpoenaed documents. Second, Janssen maintained the documents

were exempt under section 7(1)(g) of FOIA (5 ILCS 140/7(1)(g) (West 2014)) as the production

of its confidential documents would make it more difficult for a public body to induce

individuals to submit similar information in the future, i.e. such production would have a

“chilling effect.” In addition to finding the documents sought by USA Today were exempt from

disclosure pursuant to FOIA, Janssen also requested the circuit court enter a declaratory

judgment prohibiting the City from disclosing all of Janssen’s nonpublic documents to third

parties under FOIA.

¶8 After the matter was fully briefed and argued, on February 26, 2015, the circuit court

issued a written memorandum denying Janssen’s motion. Pertinent to this appeal, the circuit

court found that Janssen’s documents were not exempt from FOIA under section 7(1)(a) because

the Ordinance “in no way” implements State law. The circuit court further found that even if the

Ordinance fell within the purview of section 7(1)(a) of FOIA, sections 1-22-050(i) and 1-22­

050(k) of the Ordinance did not prohibit disclosure. Specifically, section 1-22-050(i) expressly

allowed disclosure if the City determines, in its judgment, that it is necessary for the effective

enforcement of laws. In addition, section 1-22-050(k) does not generally prohibit disclosure,

“rather, the exemption from disclosure is limited by its express terms to the [Illinois

Administrative Procedure Act (5 ILCS 100/1-1 et seq. (West 2014))].” As to section 7(1)(g) of

FOIA, the circuit court found the only party that could assert a “chilling effect” under section

7(1)(g) of FOIA was the public body in possession of the documents.

¶9 On March 23, 2015, Janssen filed its notice of appeal. Thereafter, Janssen moved to stay

Free access — add to your briefcase to read the full text and ask questions with AI

Related

City of Chicago v. Janssen Pharmaceuticals, Inc.
2017 IL App (1st) 150870 (Appellate Court of Illinois, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
2017 IL App (1st) 150870, Counsel Stack Legal Research, https://law.counselstack.com/opinion/city-of-chicago-v-janssen-pharmaceuticals-inc-illappct-2017.